CCS
STML

Crosspoint Capital Strategies’s Stemline Therapeutics, Inc. STML Stock Holding History

Crosspoint Capital Strategies’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,600
Closed -$1.03M – 111
2017
Q4 		$1.03M Hold
6,600
– – 0.09% 42
2017
Q3 		$73K Hold
6,600
– – 0.06% 47
2017
Q2 		$61K Buy
+6,600
New +$55K 0.05% 54

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Crosspoint Capital Strategies's STML Position: Q1 2018 in Review

Crosspoint Capital Strategies sold out of Stemline Therapeutics, Inc. (STML) in Q1 2018, closing a stake of 6,600 shares — an estimated $1.03M sold.

Crosspoint Capital Strategies first reported a position in STML in Q2 2017 and held it in 3 quarters. The position peaked at $1.03M in Q4 2017. 82 funds tracked by Wall St. Rank hold STML as of Q1 2018.

  • Crosspoint Capital Strategies reported no remaining Stemline Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 6,600 Stemline Therapeutics, Inc. shares in Q1 2018, an estimated $1.03M.
  • Crosspoint Capital Strategies first reported a position in Stemline Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • Crosspoint Capital Strategies's Stemline Therapeutics, Inc. position peaked at $1.03M in Q4 2017.
  • 82 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2018, filed 14 May 2018.